All News
Novel Proteomic Biomarker Set in Osteoarthritis
NIH funded researchers from Duke University have developed a set of serum proteomic biomarkers that successfully predict clinically relevant knee osteoarthritis (KOA) progression (both structural change and joint pain) over a 2 year period.
Read Article
Physician Burnout Remains, Less So in Rheumatology
The 2023 Medscape Survey on Physician burnout ranks rheumatology at #10; which is down from #2 when the survey was last done in 2021.
Read Article
Herpes Zoster with JAK Inhibitors
A recent review a higher HZ risk with JAKi therapy shows the HZ-risk in RA and UC to be higher than PsA when treated with usual doses of TOFA, especially those given higher TOFA doses or concomitant glucocorticoids.
https://t.co/rlYXJWONyS https://t.co/nwqbbp6Ci3
Links:
Dr. John Cush RheumNow ( View Tweet)
Is JAKi therapy safe in RA-ILD pts? Italian retrospective study (2018-June 2022) w/ 43 RA pts & HRCT proven ILD (med age 69yrs) & Rx w/ JAKi. After 19 mos F/U, the FVC was stable in 79%, improved in 11%, & worse in 11%. DLCO & HRCT trend was similar. https://t.co/T0rP96FM0Z https://t.co/W8NFtfevQg
Links:
Dr. John Cush RheumNow ( View Tweet)
Rretroperitoneal fibrosis Tx is fraut-steroids, tamoxifen, MMF, B cell therapy? OL trial in 8 RPF pts used steroids & mTOR inhibitor sirolimus (2mg/d x 3d; 1mg/d); 12 & 48wks - decr in fibrous tissue 50%, ESR 70%, IgG4 50% w/ normalized renal funct.
https://t.co/LbptMLCiJO
Links:
Dr. John Cush RheumNow ( View Tweet)
Can something as simple as a cup of coffee with milk have an anti-inflammatory effect in humans?
Apparently so, according to a new study. A combination of proteins and antioxidants doubles the anti-inflammatory properties.
https://t.co/vuZwsrojwH https://t.co/NFNqHOKuOz
Links:
Dr. John Cush RheumNow ( View Tweet)
FDA has approved the 1st BTK (Bruton’s tyrosine kinase) inhibitor (Jaypirca™ or pirtobrutinib) for adults with refractory mantle cell lymphoma. BTK inhibitors are also being developed for use in MS, RA, SLE, pemphigus & more https://t.co/599tK21H1Z https://t.co/KSqMMDWmfd
Links:
Dr. John Cush RheumNow ( View Tweet)
US Postage, circa 1949 "The Doctor" from a painting done by Sir Luke Fildes, “The Doctor” 1891. Portrays the values of the ideal physician and the inadequacies of the medical profession. Child in a 'crisis' (forefront) and ' dawn' light represents hope. https://t.co/OaECk6MlMZ
Dr. John Cush RheumNow ( View Tweet)
Jan 2023 Medscape Physician Burnout Report: lists Rheum @ #10 (down from #2)
1 Emergency med 65%
2 Int med 60%
3 Peds 59%
4 OB & ID 58%
5 Family med 57%
6 Neuro, Anesth 55%
7 Pulm, XRay 54%
8 Onc, GI 52%
9 Surgery, Endo 51%
10 Rheum 50% https://t.co/n66oi1Ah73 https://t.co/qTF4t2NTca
Links:
Dr. John Cush RheumNow ( View Tweet)
German survey on telemedicine (TM) in 438 MSK patients - 63% response; showed reasons against interest in TM included:
- Not yet diagnosed
- No prior TM
- Bad health status
- Rural living
- Not owning electronic device
- Aged 60-80 yrs https://t.co/niO00pCuTY https://t.co/07KFNWMs1N
Links:
Dr. John Cush RheumNow ( View Tweet)
ACR Urges CMS to Reconsider Copay Assistant Programs in CMS Proposed Rule
The Health and Human Services Notice of Benefit and Payment Parameters proposed rule for 2024 does not revise policies related to copay assistance and patient deductibles.
https://t.co/vfXFwpGJHf https://t.co/PCa53ctowL
Links:
Dr. John Cush RheumNow ( View Tweet)
For years, in my patient questionnaires, I'd ask “how high is your stress level?" Everyone said “high”, regardless of demographics. I removed “stress” from the survey, as it wasn’t a symptom; it appears the burden we carry.
Read on...
https://t.co/sLG3dktgRS https://t.co/oPJeQsnodR
Links:
Dr. John Cush RheumNow ( View Tweet)
Feb 3rd, today is #NationalWomenPhysiciansDay. The date honors Dr. Elizabeth Blackwell, 1st woman to receive an MD United States (1849). RheumNow will devote the whole month of April 2023 to our Campaign on Women in Rheumatology - stay tuned! https://t.co/l1M56L8h9N https://t.co/eQpetW02CE
Links:
Dr. John Cush RheumNow ( View Tweet)
Join us on 3/18 and 3/19 in Dallas, Texas, or virtually for RheumNow Live!
Among our 24 speakers, Dr. Sergio and Monica Schwartzman will cover All in the Family Rheumatology. Dr. Philip Conaghan will cover Insights into the Future of OA and more.
https://t.co/plpNqGu1HI https://t.co/mgMox5SpGN
Links:
Dr. John Cush RheumNow ( View Tweet)
PNAS has a novel approach to #RA Tx; bioengineered probiotic(Lactobacillus reuteri) orally delivers a peptide Kv1.3 channel blocker to RxRA. Kv1.3 is expressed on CCR7− effector memory T cells. Blocking Kv1.3 improves RA & PSO in rat models. https://t.co/DyyXi2GUH2 https://t.co/8nDyFv9DWx
Links:
Dr. John Cush RheumNow ( View Tweet)
Deptof Veterans Affairs has awarded $1.2 million to Matlock Jeffries, MD of the Oklahoma Medical Research Foundation to study the connection between obesity, gut microbiome and cartilage changes leading to osteoarthritis of the knee. CONGRATS @matlockj https://t.co/M3807QD5K2 https://t.co/ypJNunbWWS
Links:
Dr. John Cush RheumNow ( View Tweet)
Swiss RA registry assessed outcomes after 1st JAKi. 400 RA pts starting/failing JAKi were switched to 2nd JAKi or TNFi or other MOA biologic. ~40% had prior bDMARDs. Retention was higher w/ 2nd JAK (918d)i vs other options. TNFi (335d) or OMA (918d). https://t.co/3A3KwVcTCN https://t.co/UFLPGfmzNv
Links:
Dr. John Cush RheumNow ( View Tweet)
Herpes Zoster with JAK Inhibitors
A recent review a higher HZ risk with JAKi therapy shows the HZ-risk in RA and UC to be higher than PsA when treated with usual doses of TOFA, especially those given higher TOFA doses or concomitant glucocorticoids.
https://t.co/BO7CgcuRKR https://t.co/gyMivn5YxL
Links:
Dr. John Cush RheumNow ( View Tweet)
Is JAKi therapy safe in RA-ILD pts? Italian retrospective study (2018-June 2022) w/ 43 RA pts & HRCT proven ILD (med age 69yrs) & Rx w/ JAKi. After 19 mos F/U, the FVC was stable in 79%, improved in 11%, & worse in 11%. DLCO & HRCT trend was similar. https://t.co/bAqa5wKIYE https://t.co/LnlcQtQnm8
Links:
Dr. John Cush RheumNow ( View Tweet)